Supernus Pharmaceuticals (SUPN) Interest Expenses (2011 - 2023)

Supernus Pharmaceuticals (SUPN) has 13 years of Interest Expenses data on file, last reported at $910000.0 in Q2 2023.

• Interest Expenses for Q2 2023 came in at $910000.0, down 49.72% year-over-year; the trailing twelve-month figure through Mar 2024 was $910000.0 (down 86.28% YoY), and the FY2023 annual result was $2.4 million, down 65.84% from the prior year.
• Interest Expenses declined to $910000.0 in Q2 2023 per SUPN's latest filing, from $1.5 million in the prior quarter.
• Over five years, Interest Expenses peaked at $6.1 million in Q1 2021 and troughed at $910000.0 in Q2 2023.
• A 5-year average of $4.4 million and a median of $5.7 million in 2019 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2019 and 2022: Interest Expenses surged 718.69% in 2019, then tumbled 73.14% in 2022.
• A 5-year view of Interest Expenses shows it stood at $5.8 million in 2019, then gained by 5.52% to $6.1 million in 2020, then decreased by 2.66% to $5.9 million in 2021, then sank by 73.14% to $1.6 million in 2022, then tumbled by 42.91% to $910000.0 in 2023.
• Business Quant data shows SUPN's Interest Expenses at $910000.0 in Q2 2023, $1.5 million in Q1 2023, and $1.6 million in Q4 2022.